A Canadian Cost Analysis Comparing the Use of Bortezomib or Lenalidomide as Maintenance Therapies in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant
Abstract
Authors
R. LeBlanc J. Tay S. Hollmann J. Shustik